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Objective: To survey the evolution over the past decade of attitudes and practices of obstetricians in maternal–
fetal medicine fellowship programs regarding the management of human immunodeficiency virus (HIV)-infected
pregnant women.
Methods: Directors of all 65 approved maternal–fetal medicine training programs were sent questionnaires,
responses to which were to reflect the consensus among members of their faculties. Programs were stratified
based upon the number of HIV-infected pregnant patients cared for in the previous year.
Results: Responsesreflectexperiencewithover1000infectedpregnantwomenperyear,nearlyone-quarterwith
advanceddisease. Combinationantiretroviraltherapy wasprescribedby all respondents,universallyinthe 2ndand
3rd trimesters. A three-drug regimen (often containing a protease inhibitor) was used more often by those who
treated at least 20 HIV-infected pregnant patients per year than by those programs seeing a lower number of
patients(80vs59%).Despitethe knownandunknownrisksoftheuseofantiretroviralsduringpregnancy,onlyhalf
of all responding programs report adverse events to the Antiretroviral Pregnancy Registry; reporting was more
common among the institutions seeing a higher number of patients (61 vs 45%). Seventy-eight percent of higher
volume programs enroll their patients in clinical studies, usually multicenter, versus 35% of lower volume
programs.
Conclusions: Care for HIV+ pregnant women has dramatically changed over the past decade. Antiretroviral
therapy is now universally prescribed by physicians involved in maternal–fetal medicine training programs.
Given limited experience with these agents in the setting of pregnancy, it is essential for maternal–fetal medicine
practitioners to actively report on adverse events and participate in clinical trials.
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Vertical transmission ofhumanimmunodeficiency
virus (HIV) has been dramatically reduced in the
United States and other countries where anti-
retroviral therapy is widely available, where
alternatives to breastfeeding are a viable option,
and where elective Cesarean deliveries are
selectively performed1. The relevance of mother-
to-child transmission in the United States
stems from the fact that new HIV infections
are most predominant among young women of
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Clinical study 81reproductive age, particularly adolescent minori-
ties2. Data on interventions to reduce the rate of
transmission have rapidly evolved over the past
decade. A placebo-controlled trial demonstrating
clear benefits of the administration of antiviral
therapy to pregnant women and neonates was
published in 1994: the Pediatric AIDS Clinical
Trials Group (PACTG) 076 study3. The impact of
this regimen has been proven in follow-up
epidemiologic studies, demonstrating a reduction
in perinatal AIDS cases in the United States from
the years 1992 to 1997 by 67%4. A significant
proportionofthisbenefitisthoughttoberelated to
the reduction of plasma HIV-1 viral load as dem-
onstrated in the PACTG 185 study and the
Women and Infants Transmission Study (WITS),
enrollingwomenwith more advanced disease than
those in the PACTG 076 group5,6. Scheduled
Cesarean delivery, particularly for mothers with
high plasma levels of HIV, performed before the
onset of labor and before the rupture of mem-
branes, has proven to be effective in reducing the
rate of transmission of virus as evidenced in a
meta-analysis performed by the International
Perinatal HIV Group. However, most of the
studies in that analysis were conducted before
the widespread use of highly active antiretroviral
therapy (HAART)7.
The dissemination of information on the
management and therapy of HIV-infected preg-
nant women has come via both public and private
sources. The US Department of Health and
Human Services Public Health Service publishes
recommendations for the use of antiretroviral
therapy in HIV-infected pregnant women. The
most recent revision was in February 2001; at the
time this survey was performed, the most recent
revision had been on January 30, 1998. The
current guidelines strongly recommend the use
of these agents for the purposes of addressing two
separate but related issues – antiretroviral therapy
to treat the mother’s HIV infection and anti-
retroviral chemoprophylaxis to reduce the risk of
perinatal HIV-1 transmission8. The American
College of Obstetricians and Gynecologists
(ACOG) has issued several policy statements and
committee opinions regarding the treatment of
HIV-infected pregnant women, which are con-
stantly being updated and revised9–12.
For more than 26 years the American Board of
Obstetrics and Gynecology (ABOG) has certified
obstetrician–gynecologists for special competence
in maternal–fetal medicine. The 65 currently
approvedfellowshipprogramsthattraincandidates
for subspecialty certification are periodically
reviewed for accreditation based upon demon-
strated continued academic and clinical compe-
tence in the management of all complications
of pregnancy. In 1991 an initial survey of the
management and therapy of HIV-infected
pregnancies in maternal–fetal medicine training
programs was conducted13. Much has evolved
in the field, leading to dramatic reductions in
transmission, yet there is still a lack of uniformity
in treatment strategies. The purpose of this
study is to characterize current opinions and prac-
tices among maternal–fetal medicine practitioners
and contrast them with the study performed in
1991.
SUBJECTS AND METHODS
In August 1999 a 30-item questionnaire concern-
ing issues in the management of HIV-infected
pregnant women was sent to the directors of the
65 approved training programs in maternal–fetal
medicine in the United States. This was in
follow-up to an initial study conducted during
1991–1992. The directors were asked to answer
each question in a manner reflecting the consensus
among the members of their division. Two
follow-up mailings and telephone contacts were
made to facilitate questionnaire completion. By
May 2000 the directors of 41 of the 65 programs
(63%) had returned completed questionnaires and
the data were compiled and analyzed.
Respondents were stratified into two groups
based on the number of HIV-infected pregnant
patients seen at their institution within the
previous year – either greater than or equal to 20
patients (18 programs) or less than 20 patients
(23 programs). Differences in responses were ana-
lyzed using either c2 analysis or Fisher’s exact test.
Clinically significant trends were reported; they
were not statistically significant unless otherwise
noted.TheSAS6.12 statistical packagewasusedin
these analyses (SAS Institute, Inc., Cary, NC).
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Forty-oneof the65 currently approved fellowship
training programs responded to our survey,
representing a nationwide sample of programs
with varied size among 23 states. There were 13
fewer active fellowship programs in 1999 than
there were in 1991. The1991 survey was based on
the experience of 381 370 pregnancies – in 2105
of which the mother was HIV-positive (HIV+) –
while the current survey is based on a sample of
143 037, in which 1007 of the mothers were
HIV+. The data represent approximately
one-sixth of the estimated 6000 HIV-infected
womenwhodeliver eachyearintheUnitedStates.
Some large programsin New York,California and
Illinois did notrespond,for unknownreasons, and
thus their experience is not reflected in the survey
results. Theprogramswhichsee 20 ormore HIV+
pregnancies per year are actually seeing over
three-quartersofallHIV+ pregnantwomeninthis
study. Five (12%) of the responding programs see
fewer than five pregnancies complicated by HIV
peryear.Theproportionofwomenwithadvanced
(CD4+ cell count < 200 cells/mm3) or symptom-
atic disease has increased from approximately 20%
in 1991 to approximately 25% in 1999, despite
the more widespread use of potent antiretroviral
therapy. The clinics of maternal–fetal medicine
fellowship training programs are more likely to
register patients with HIV-related complications,
thus women with advanced HIV disease may be
overrepresented in our sample.
Table 1 presents the demographic characteris-
tics of all respondents and of the stratified groups.
Thereare153 037deliveries performedannuallyat
the41 maternal–fetal medicine programs surveyed
(mean 3732.61; range300–14 700perinstitution).
On average, approximately 1007 HIV-infected
pregnant women (mean 24.56; range 0–130 per
institution) receive care in the clinics of these
training programs each year; 229 with CD4+
lymphocyte counts < 200 cells/mm3 (mean 5.59;
range 0–25 per institution). Thus, nearly one-
quarter of all pregnancies complicated by HIV
which were included in this survey involve
women with advanced disease. Fifty-nine percent
(24 of41)oftheseprogramshavea specialclinicfor
HIV-infected pregnant women. Eighty percent
(33 of 41) of the program directors surveyed stated
that additional medical specialists outside their
divisional staff assist in the management of HIV-
infected patients.
HIV testing is uniformly offered by all the
responding programs; however, only 79% of
patientsconsentedto testing.Prenataltesting iden-
tified 406 new HIV diagnoses per year among the
41 surveyed institutions (mean 9.90; range 0–40).
Thus 40% of all HIV-infected pregnant women in
these institutions are being diagnosed as part of
these prenatalscreening efforts. Women presented
for prenatal care, on average, during either the 1st
(45%) or 2nd (55%) trimester.
Table 2 summarizes the responses of program
directors regarding attitudes towards the use of
antiretrovirals during pregnancy. Antiretrovirals
were prescribed during pregnancy by all respon-
dents, universally in the 2nd and 3rd trimesters.
Although there are differences of opinion on
whether or not to start antiretrovirals during the
1st trimester, none of the respondents would
recommend stopping therapy if a patient was
already receiving it. All surveyed program direc-
tors recommended the use of combination
therapy (two or more drugs) during pregnancy. A
three-drug regimen was used more often by those
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Centers with
Characteristic
All respondents
(n = 41)
‡ 20 HIV+
pregnancies per year
(n = 18)
< 20 HIV+
pregnancies per year
(n = 23)
Deliveries/year
HIV+ deliveries / year
HIV+ deliveries / year with CD4 count < 200 cells/mm3
153 037 (3732.61)
1006.5 (24.55)
228.5 (5.57)
85 677 (4759.83)
783.5 (43.53)
164 (9.11).
67 360 (2928.70)
223 (9.70).5
64.5 (2.80)
HIV+, human immunodeficiency virus-positive
Table 1 Characteristics of responding institutions (totals (means))who treat more than 20 HIV+ patients per year
(80 vs 59%). The most common modification of
the PACTG 076 regimen, which is based on
zidovudinemonotherapy,involved achangeinthe
oral zidovudine dosing to twice-a-day dosing,
with the addition of lamivudine (Combivir®
(GlaxoSmithKline, Research Triangle Park,
NC)). Other modifications involved the co-
administration of a protease inhibitor as part of a
three-drug regimen. Zidovudine still remained
part of the prescribed regimen for the majority of
respondents (68%). Strict inclusion of zidovudine
as part of a combination regimen was more
common in the group seeing fewer than 20 HIV+
pregnancies per year (74 vs 61%). Sixty-nine per-
cent of all respondents took into account prior
antiretroviral exposure when designing a treat-
ment regimen, more commonly in the experi-
enced group of providers (78 vs 62%).
Eighty-seven percent of surveyed institutions
routinely measured HIV-1 RNA levels, which are
used to assist in treatment recommendations.
When asked if there were specific antiretroviral
agents that were avoided during pregnancy, only
13 of 41 programs responded. Of those 13,
10 specifically mentioned efavirenz, most citing
its teratogenic potential as demonstrated in
animal models. Others listed some of the newer
agents (abacavir, amprenavir), citing unfamiliarity
or minimal experience with these agents. One
program director cited indinavir, and mentioned
concerns about drug-induced hyperbilirubinemia
and its potential effects on the fetus. Despite the
known and unknown risks of the use of antiretro-
virals in pregnancy, only half of all programs were
reporting adverse events to the Antiretroviral
Pregnancy Registry (see below); reporting was
more common in those who saw 20 or more
HIV+ pregnancies per year (61 vs 45%). Respon-
dents were surveyed as to whether they had
noticed an increased incidence of gestational dia-
betes in their patients on protease inhibitors; the
majority (90%) had not. However, several pro-
grams had altered their screening practices for
gestational diabetes, a situation more common
among those programs seeing more HIV-infected
pregnantmothers (28 vs 14%). Theoverall strategy
of these altered screening practices was to begin
earlier inpregnancyandtoscreen morethanonce.
Programdirectorswereaskedaboutthepractice
patterns of their divisions in relation to the use
of specific algorithms for managing HIV in
pregnancy and regarding participation in clinical
studies in the management of HIV infection in
pregnancy. It was more common for programs
seeing a larger number of patients to have
developed such an algorithm for managing HIV
in pregnancy (78 vs 35%). Seventy-eight percent
of programs which saw 20 or more HIV+ preg-
nancies per year enrolled their patients in clinical
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Centers with
Characteristic
‡ 20 HIV+ pregnancies
per year
< 20 HIV+ pregnancies
per year
Prescription of antiretrovirals in first trimester
Selection of antiretrovirals based on prior exposure
Zidovudine (AZT) always part of regimen
Reporting of adverse events
Increased gestational diabetes on PIs
Altered screening practices for gestational diabetes in patients on PIs
17/18 (94.44)
14/18 (77.78)
11/18 (61.11)
11/18 (61.11)
3/18 (16.67)
5/18 (27.78)
16/20 (80.00)
13/21 (61.90)
17/23 (73.91)
10/22 (45.45)
1/22 (4.55)
3/22 (13.64)
PACTG 076 regimen – zidovudine dosing
Strict
Modified
Number of drugs included in antiretroviral regimen
Two drugs
Three drugs
7/18 (38.89)
11/18 (61.11)
3/15 (20.00)
12/15 (80.00)
12/22 (54.55)
10/22 (45.45)
7/17 (41.18)
10/17 (58.82)
HIV, human immunodeficiency virus; PI, protesae inhibitor; PACTG, Pediatric AIDS Clinical Trials Group
Table 2 Respondents’ attitudes towards the use of antiretrovirals in pregnancy (n (%))studies, as compared with 35% of those which see
less than 20; this difference was statistically signifi-
cant (p = 0.006). Almost universally, these studies
were multicenter.
Eighty percent of responding institutions
offer termination of pregnancy to HIV-infected
pregnant patients; acceptance was 9% on average.
Sixty-three percent of institutions would recom-
mend elective Cesarean sections to those HIV-
infected pregnant patients not on HAART; if on
HAART the recommendation would only be
made by 35% of programs. Seventy-nine percent
of responding program directors reported that the
standard in their practices was to alter obstetric
techniques in pregnancies complicated by HIV.
The most common alterations were avoiding early
rupture of membranes and artificial rupture of
membranes, active management of labor to expe-
dite delivery, avoiding the use of scalp electrodes
and other forms of invasive monitoring, avoiding
theuseofforceps,andavoidingtheperformanceof
episiotomies. Over half (53%) of respondents
perceived thatpregnantwomeninfectedwithHIV
were at increased risk of maternal–fetal complica-
tions;thisperceptionwasstrongestamongthepro-
grams seeing the majority of HIV-complicated
pregnancies (61 vs 45%). Specific questions were
asked regarding recommendations for and perfor-
manceofamniocentesis/chorionicvillus sampling.
The majority of institutions would offer amnio-
centesis or both if indicated and desired (32%
amniocentesis alone, 32% both).There was almost
unanimous recommendation against breastfeeding
(95%).Interestingly,thetwodissentinginstitutions
were among the group seeing a higher volume of
HIV-infected pregnant women.
DISCUSSION
The past decade has been one of extraordinary
progress in our understanding of the epidemic of
vertically transmitted HIV. Through the efforts
of ACOG, the Society for Maternal–Fetal
Medicine, the US Public Health Service and
others, this information has been disseminated,
establishing updated standards of care with great
success. The results of this study demonstrate,
however, that there are still areas of considerable
controversy. While the benefits of HAART
administered to women to alter the progression of
their ownHIV disease are clear,whethertheuse of
theseregimens inpregnancy,particularlywhenthe
maternal HIV-1 RNA level can be suppressed
below 1000 copies/ml, will provide superior risk
reductionovertheuseofzidovudineortheperfor-
mance of elective Cesarean section is not yet
known.
Many of the changes in practice identified since
1991 are a reflection of advances in the care of all
patients with HIV infection. The current survey
was meant to pool experience and opinions relat-
ingtonewerconceptsin thefield of maternal–fetal
medicine; when appropriate, comparisons were
made with the initial 1991 survey. Recall bias may
have affected some of the estimates reported by
the program directors. However, as part of the
recertification process, fellowship program direc-
tors are required periodically to report the size and
composition of their obstetric population to
ABOG. It has become increasingly common for
institutions to have a special clinic (i.e. separate
from the general obstetrics clinic) set up to care for
pregnant patients with HIV infection; in 1999
59% of responding programs had established such
a clinic, while in 1991 only 40% had established
one. The assistance of experts outside divisions of
maternal–fetal medicine, such as infectious disease
specialists, remains very common, although there
has been a decline (85% of respondents in 1991,
80% in 1999). More institutions have developed
specific algorithms for the management of these
patients (56% in 1991, 63% in 1999).
The perception that HIV-infected pregnant
women are at higher risk of obstetric complica-
tions has remained constant over the period
1991–1999 at approximately 50% of respondents.
However, the trend towards offering/recom-
mending termination of HIV+ pregnancies has
decreased from90% in1991downto80%in1999,
perhaps reflecting increased confidence in the use
of antiretroviral therapy and other measures to
reducevertical transmission. Inregardtoantiretro-
viral therapy, in 1991 the only option available
was zidovudine. Although the initial survey was
conducted prior to the publication of the results
of the PACTG 076 study, there was still much
anticipation of the potential benefits of antiviral
therapy in reducingmother-to-child transmission,
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offered to asymptomatic HIV-infected pregnant
womenand 95%believing thatit shouldbeoffered
to symptomatic patients. In 1999 antiretrovirals
were universally recommended.
The results of PACTG 367 give support to
the results of this survey. This study represents a
retrospective abstraction of prenatal data from one
of the PACTG sites (464 women)14. Of HIV-
infectedwomenwhodelivered atthatsitebetween
January 1998 and May 1999, 54% knew their HIV
status prior to pregnancy while 44% were diag-
nosed during pregnancy, similar to the approxi-
mately 40%notedinoursurvey.Stageofdisease, as
approximatedbyCD4+cellcount,wasalso similar
between our population and that in the PACTG,
with 20% and 25%, respectively, having counts
< 200 cells/mm3.
Drugs such as protease inhibitors and non-
nucleoside reverse transcriptase inhibitors
(NNRTI) have only been available for the past 6
years; their long-term toxicities in adults, let alone
their effects in utero, are still largely unknown.
Some results from French and Swiss studies – not
substantiated in the United States experience –
give cause for concern, as they suggest potential
mitochondrial toxicity from the use of nucleoside
reverse transcriptase inhibitors(NRTI) and poten-
tial premature births from the use of protease
inhibitors15,16. In the most recent Public Health
Service guidelines, coadministration of stavudine
(d4T) and didanosine (ddI) for HIV-infected
women has been discouraged secondary to reports
of maternal morbidity related to lactic acidosis8.
Alarmingly, only 50% of responding programs
submitted information on adverse effects to the
AntiretroviralPregnancyRegistry. Thepurposeof
this registry is to collect data on antiretroviral
exposure during pregnancy to assess the terato-
genic potential of these drugs. It is a collaborative
project of the pharmaceutical manufacturers with
an advisory committee of obstetric and pediatric
practitioners. Given the limitations in our knowl-
edge base, it is essential that data be collected on
the experience of all pregnancies where antiretro-
virals are used, not just at the higher volume
centers (Antiretroviral Pregnancy Registry, 140
Commonwealth Drive, Wilmington, NC 28403;
phone: (800) 258-4263, fax: (800) 800-1052).
It is also of utmost importance for studies to
be conducted evaluating the impact of protease
inhibitors on the development of gestational
diabetes, a significant cause of morbidity for both
mother and child. A growing body of evidence
implicates these agents as causative agents of the
lipodystrophy syndrome, characterized by insulin
resistance, dyslipidemia and fat redistribution.
Another area for future research relates to the
implications of antiretroviral resistance developing
in women and children exposed to these agents in
the perinatal period.
CONCLUSION
In many ways, vertically transmitted HIV is a very
preventable disease; eradication is within therealm
of possibility in countries with the resources of
antiretrovirals and alternatives to breastfeeding.
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